Scheduled to allow mass vaccination in the coming months in France, the vaccine developed by the tricolor pharmaceutical company Sanofi should not be available before the end of the year at best.

To get out of the rut, one avenue studied by the authorities would be to produce competing vaccines in Sanofi factories.

Communication, logistics ... The vaccination campaign against Covid-19 is criticized on various aspects in France.

But another complication could be added to the large-scale mission that the French authorities are trying to carry out: the delay in the vaccine developed by the French pharmaceutical company Sanofi.

Admittedly, this vaccine was never expected to be available at the start of the year.

At best, the product was expected in June.

For the moment, therefore, the 300 million doses ordered from Sanofi are not lacking.

But they could ultimately still be lacking, which greatly worries the authorities as Europe 1 explains to you.

>> LIVE

- Coronavirus: follow the evolution of the situation Thursday, January 7 

Sanofi could produce competing vaccines in its factories

Indeed, Sanofi's vaccine will not be available before the end of 2021 in the best-case scenario.

This could pose a problem in the coming months in France, because these doses must be used in particular for the mass vaccination planned in the coming months.

>> Find Europe Matin in replay and podcast here

How to explain it?

Sanofi simply had to get back to work.

The first version of his vaccine was not effective enough, especially with regard to the elderly.

The company will resume its phase two clinical trials within a few days.

The results are expected in May.

If they are conclusive, it will still be necessary to carry out those of phase three.

Here again, the stage could take longer than expected: as other vaccines have already been licensed, this phase three is more complicated to carry out.

CORONAVIRUS ESSENTIALS

> Covid-19 vaccines: what do we really know about their side effects?

> What do we know about "long Covid", these patients who are going through hell?

> These three facets of the coronavirus that you may not have heard of

> When are we in contact?

And other questions that we ask ourselves every day

> Coronavirus: the 5 mistakes not to make with your mask

Discussions are underway to try to develop a procedure that could limit the delays as much as possible.

And the file is followed like milk on fire by the French authorities.

The pressure is immense for the company.

According to information from Europe 1, one of the avenues on the table to get out of the rut would be to produce in Sanofi factories the other available vaccines, such as that of AstraZeneca.

All this time to finalize the French vaccine ... An official French source confirms that the track is under study.

Sanofi has 18 production sites in the country.